RESULTS:
Ten studies (255 patients) were included. Of these, 123 patients were injected with botulinum toxin type A, nine patients were offered botulinum toxin type B and the remaining 123 patients represented the control groups. Significantly improved cosmetic outcomes were observed among certain studies using the visual analogue scale (experimental group: median score 8.25 [range 6 to 10]) versus control group: median score 6.38 [range 2 to 9]; P<0.001) and the Stony Brook Scar Evaluation Scale (experimental group score: 6.7 versus control group score: 4.17; P<0.001) assessments. However, the methodological heterogeneity of the included studies, the lack of control group in the majority of them, the use of subjective scales of measurement and the frequent use of patient self-assessment precluded unbiased results. CONCLUSIONS: Current evidence does not support the usage of botulinum toxin. Future randomized controlled trials are needed in the field to reach firm conclusions regarding its place in current clinical practice. searched, minimizing the loss of articles. All articles that met or were presumed to meet the inclusion criteria were retrieved in full text. Search strategies and results are shown in Figure 1 .
Medline ). Scopus, Popline and CENTRAL were searched using terms "botulinum AND scar" and "botulinum AND wound". Clinical trials.org was searched using the term "botulinum".
Definitions
The Patient Scar Assessment Scale (PSAS), Observer Scar Assessment Scale (OSAS) (also known together as Patient and Observer Scar Assessment Scale [POSAS]), Vancouver Scar Scale (VSS), Visual Analogue Scale (VAS) and modified Stony Brook Scar Evaluation Scale (SBSES) are widely used scales of measurement that quantify the response to therapy concerning scar appearance. The VSS objectively evaluates four parameters of healing: vascularity, height/thickness, pliability and pigmentation. The PSAS and OSAS (POSAS) expands the included symptoms of pain and pruritus that are subjectively described on objective data captured in the VSS. The VAS measures pigmentation, vascularity, acceptability and observer comfort and contour by using photographs. The modified SBSES is a six-level scale that estimates short-term aesthetic results of wound healing by evaluating width, colour, height and visibility of the incision line. All these scales have been previously evaluated and seem to correlate well with the cosmetic VAS, with the exception of the PSAS, in which data are limited because it is mainly used as a component of the POSAS scale (9) (10) (11) (12) . However, the POSAS seems to be the most comprehensive because it takes in account both the patient's personal and the observer's objective perspectives (13) .
The cosmetic result of wound healing after the application of botulinum toxin, as well as major and minor complications of its use, were the main outcome of our study.
RESULTS
Ten studies were included in the present systematic review (Table 1 ) (14-23). In total, 255 patients were enrolled. Of these, 123 patients experienced scar wounds or keloids and were injected with botulinum toxin type A (BTA). Nine patients were offered botulinum toxin type B. The remaining patients represented the control groups.
Characteristics of included studies and potential bias
Ziade et al (17) included 24 patients with facial wounds in a singleblind randomized controlled trial. Exclusion criteria included allergy to botulinum, known breastfeeding, myasthenia or previous injection of botulinum within a six-month interval. The 'toxin' group was injected with BTA and the 'control' group did not receive an injection. The injection was performed in the facial muscles involved in scar widening. They did not describe the process of randomization. The results were interpreted with PSAS, OSAS, VSS and VAS scales of measurement (17) .
Gassner et al (22) included 31 patients who experienced forehead wounds (traumatic or after neoplastic excision) in their single-blind randomized controlled trial. Exclusion criteria were current pregnancy, breastfeeding, history of irradiation and or chemotherapy, hematological disorders, neuromotor disorders and keloid formation. Among the 31 patients, 16 received BTA treatment while the rest were given preservative-free normal saline. The injections were performed in the underlying musculature covering a diameter of approximately 1 cm to 3 cm around the scar's edges. The randomization was performed using blocks of random numbers. They did not describe the method of allocation concealment (22) .
Xiao et al (20) included 19 patients who had a single hypertrophic lesion (any location) for more than two years in a prospective, uncontrolled observational trial. Lesion volumes ranged from 2.5 cm 3 to 35 cm 3 . Exclusion criteria included any kind of therapy during the previous year and during the time after the beginning of the therapy, current pregnancy, planned pregnancy, chronic renal failure, breast feeding, pathological liver and blood cell control. The wound was injected with BTA using a needle in three-monthly intervals. The dose of the toxin depended on the size of wound, but no more than 100 U per treatment (20) .
Kim et al (14) included 15 patients >18 years of age with a recent (<10 days) thyroidectomy neck scar with a mean length of 8 cm in a randomized, controlled split-scar study. Excluded were patients who were allergic to botulinum toxin, pregnant or lactating, suffering from myasthenia, injected with the toxin in the previous six months and those who refused to participate. Patients were injected with a 31-gauge, 8 mm needle with BTA (100 U) mixed with 0.9% saline on one-half of the scar and 0.9% saline on the other. The exact point of injection was not mentioned. The randomization was based on a generator setting the left or right side with number 0 or 1. Both the patients and the dermatologist performing the injections were blinded, while the other examiners were absent from the injection room (14) .
Wilson (23) included 40 patients with traumatic facial wounds undergoing scar revision surgery. The type of study was not available. Patients with traumatic scars in the forehead and the cheek, 3 cm to 18 cm in length, were included in the study, excluding those with scars of burn origin. Patients were injected with a mix of a crystallized BTA 100 U, sodium chloride 0.9 mg and human albumin 0.5 mg diluted with normal saline immediately following scar revision surgery; the injections were performed with an insulin syringe into the musculature around the wound in a diameter of approximately 3 mm to 4 mm around the edges (23).
Gauglitz et al (18) included four patients with keloids that had persisted for more than two years. The patients had not received other forms of treatment during the previous six months. The injections were performed inside the keloid scar in bimonthly intervals by using a 24-gauge needle and a dose of 70 to 140 Speywood units of BTA. The treatment lasted for a maximum of six months (18) .
Robinson et al (16) included 12 patients with keloids located on the sternum, neck, thigh or cheek after burn injuries, skin surgery or idiopathic in nature. Neither the type of study nor the exclusion criteria were available. The BTA therapy lasted, on average, 11 months without reference to the exact point and time of the injection (16). 
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Zhibo and Miaobo (24) included 12 patients with chest, shoulder and earlobe keloids in their prospective uncontrolled observational trial. Inclusion criteria included no keloid treatment of any kind in the previous three months. The exclusion criteria were not mentioned. Patients were injected with 70 U to 140 U of BTA per scar with a 24-gauge needle every three months for approximately nine months. The exact point of injection was not mentioned (24) .
Wilson (15) included 80 patients with presternal, facial, trunk, earlobe and arm keloids present for a mean of 1.3 years. The type of study was not mentioned. The keloids were a result of surgical scars, trauma, puncture of the earlobe and infections of the skin. Exclusion criteria included duration of the keloid less than one year, lack of extension of the keloid and the existence of a keloid after a burn. Nine days after the surgical excision, the patients were injected once with 50 mg/mL of 5-fluorouracil (together with 50 IU/mL of BTA) using a 30-gauge needle. The injections were both intradermal and subdermal around the edges of the scar (15) .
Flynn (19) included 18 patients who underwent Mohs micrographic surgery and reconstruction for nonmelanoma skin cancer or melanoma in situ in a retrospective uncontrolled observational trial. All lesions were located on the forehead and frontalis region, the nose, the chin, the glabella, the scalp and the zygoma. Nine patients received BTA and nine botulinum toxin B. They included patients with postsurgical scars that influenced the subjacent muscles and the movements of the skin. Exclusion criteria were not mentioned. The injection was performed in the underlying muscles 1 cm to 2 cm around the edges of the incision every 0.7 cm to 1.0 cm. The dose of the toxin depended on the muscle group (19) .
Main outcomes
An analysis of the included studies revealed the outcomes were heterogeneously reported. Specifically, some studies reported their results based on the patients' satisfaction (eg, PSAS), whereas others were based on independent observers (eg, OSAS or VSS) or on treating doctors (eg, VAS). Subjective score scales as well as photographic records were also used.
In two studies, VAS scores were significantly improved among patients who received BTA compared with controls (median score 8.25 [range 6 to 10] versus median score 6.38 [range 2 to 9]; P<0.001), and (8.9 versus 7.2; P=0.003) (17, 22) . However, this was not observed using other measurement scales (PSAS, OSAS, VSS). The VSS was also utilized by Robinson et al (16) , who reported improvement in the appearance of the scar in all but four patients, who experienced recurrences. Similarly, the SBSES revealed a statistically significant difference between the two sides of the scar (6.7 versus 4.17; P<0.001) in the Kim et al (14) split-scar study. Three studies suggest an improved cosmetic result based both on patients' subjective opinion and analysis of photographic records (19, 23, 24) . Xiao et al (20) further strengthened their results using independent observers. The same researchers (21) also described a statistically significant reduction in erythema, pliability and itching scores (P<0.01). Wilson (15) based their results on patient selfreport; in this study, the majority of patients (83.75%) evaluated their outcomes as significantly improved (15). Gauglitz et al (18) found no change on the total appearance of the keloid when it was measured objectively with a three-dimensional profiling system.
Major complications related to botulinum injection such as ptosis of the upper lid, drooling, problems with mastication, muscle weakness and infection were not described. However, minor complications such as pruritus, burning sensation, pain, postinflammatory hyperpigmentation and mild headaches were noticed but were symptomatically treated and gradually subsided. Smile asymmetry was reported among certain patients with zygomatic scars (17, 23) .
Complications related to wound healing were also present and involved recurrences of the HS or keloids (partial and complete), atrophy of the skin, ulceration, partial wound dehiscence, late widening and an epidermal slough. However, these were seldom observed, and affected a relatively small number of patients.
DISCUSSION
The beneficial effect of BTA in the treatment of keloids and surgical wounds remains to be established. To date, several studies have been conducted to investigate its effectiveness against keloids and surgical wounds, as well as its safety. However, it seems that the existing trials, which are included in our systematic review, suffer from obvious weaknesses such as the relatively small number of enrolled patients, the subjective assessment of cosmetic improvement and insufficient stratification.
The assumption that BTA is effective on the treatment of keloids and scars is supported by in vitro and experimental animal models. BTA delays fibroblast growth by inhibiting the cell cycle and, thereby, reduces HS development (25) . In addition, BTA decreases the expression of connective tissue growth factor, which is a downstream regulator of the transforming growth factor-β1 (TGF-β1), and inhibits the growth of fibroblasts as well as the scar expansion (21) . BTA reduces the concentration of TGF-β1 in fibroblasts; in fact, the more BTA is given the most the concentration of TGF-β1 is downscaled (20) . Furthermore, BTA decreases the infiltration of inflammatory cells during wound healing, reduces fibrosis, but counterintuitively leads to extension of its length (26) . Moreover, BTA causes muscular paralysis and reduces muscle closing tension during the healing of a wound, thereby improving the cosmetic outcome in rabbit ear postoperative scars (27) . Finally, BTA inhibits collagen production and restricts wound hypertrophy in rabbit ear models as well as inhibiting fibroblasts cell cycle in vivo. The majority of fibroblasts that were not treated with BTA were mainly in the G2/M phase of the cell cycle compared with the treated ones, which were arrested in the G0/G1 phase (28) .
Strengths and weaknesses
In the present systematic review, we aimed to include all the available studies in the international literature to clearly mark out all their data that support or refute the efficacy of BTA in healing keloids and scars. The main weakness of our systematic review relies on the low methodological quality of the included trials. The number of enrolled participants is relatively small and underpowered; furthermore, with the exception of three trials (14, 17, 22) , the majority were uncontrolled studies. A very significant disadvantage of these studies is that the assessment of the effect of BTA is mainly based on the patients' perception of wound healing (24) , although some trials used objective scales such as the OSAS, the VSS and the VAS (17) .
Implications for future research
The existing data are insufficient to reach firm conclusions regarding the therapeutic effect of BTA in keloids and scars. Therefore, further research is mandated. It is our belief that a more specific stratification should be applied based on the type of wound (eg, keloids versus HS).
We also believe that surgical and trauma wounds should be differentiated. In addition, stratification according to ethnicity and age is essential because these elements affect wound healing and should, therefore, be taken in account. Studies should also consistently evaluate the assessment of treatment based on objective scales such as OSAS, VSS and VAS, which should only be interpreted by trained staff, thus avoiding the introduction of assessment bias. Finally, future trials should use control groups and enroll an adequate number of patients to achieve statistical power.
CONCLUSION
The available evidence does not support the use of BTA for the treatment or the prevention of HS. Although the underlying pathophysiological mechanisms seem to suggest its beneficial action, this is not sufficiently demonstrated in clinical studies. The main flaws of existing clinical studies rely in their poor methodological quality, which subjects them to significant bias. Future randomized controlled trials are needed to reach firm conclusions regarding its use in current clinical practice.
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